Argitalpenak (78) NATALIA AFRICA NAVAS IGLESIAS argitalpenak

2024

  1. Comprehensive Analysis of Cetuximab Critical Quality Attributes: Impact of Handling on Antigen-Antibody Binding

    Pharmaceutics, Vol. 16, Núm. 9

  2. Comprehensive physicochemical and functional analysis of pembrolizumab based on controlled degradation studies: Impact on antigen–antibody binding

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 194, pp. 131-147

  3. Improved sample introduction approach in hydrophilic interaction liquid chromatography to avoid breakthrough of proteins

    Journal of Chromatography A, Vol. 1713

2023

  1. Analysing the In-Use Stability of mRNA-LNP COVID-19 Vaccines Comirnaty™ (Pfizer) and Spikevax™ (Moderna): A Comparative Study of the Particulate

    Vaccines, Vol. 11, Núm. 11

  2. Comprehensive physicochemical characterization of a peptide-based medicine: Teduglutide (Revestive®) structural description and stress testing

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 184, pp. 103-115

  3. Practical study on the impact of injection conditions in gradient elution mode for the analysis of therapeutic proteins when using very short columns

    Journal of Chromatography A, Vol. 1709

  4. QbD/PAT—State of the Art of Multivariate Methodologies in Food and Food-Related Biotech Industries

    Food Engineering Reviews, Vol. 15, Núm. 1, pp. 24-40

2022

  1. Combined use of UV and MS data for ICH Stability-Indication Method: Quantification and isoforms identification of intact nivolumab

    Microchemical Journal, Vol. 182

  2. Comprehensive Analysis of Nivolumab, A Therapeutic Anti-Pd-1 Monoclonal Antibody: Impact of Handling and Stress

    Pharmaceutics, Vol. 14, Núm. 4

  3. Degradation and in-use stability study of five marketed therapeutic monoclonal antibodies by generic weak cation exchange liquid chromatographic method ((WCX)HPLC/DAD)

    Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, Vol. 1203

  4. Method for identification and quantification of intact teduglutide peptide using (RP)UHPLC-UV-(HESI/ORBITRAP)MS

    Analytical Methods, Vol. 14, Núm. 43, pp. 4359-4369

  5. Tracking the physicochemical stability of teduglutide (Revestive®) clinical solutions over time in different storage containers

    Journal of Pharmaceutical and Biomedical Analysis, Vol. 221

2021

  1. Non-Invasive and Spectroscopic Techniques for the Study of Alonso Cano's Visitation from the Golden Age of Spain

    Studies in Conservation, Vol. 66, Núm. 5, pp. 298-312

  2. Stability study over time of clinical solutions of ziv-aflibercept prepared in infusion bags using a proper combination of physicochemical and functional strategies

    Journal of Pharmaceutical and Biomedical Analysis, Vol. 203

  3. The relevance of monoclonal antibodies in the treatment of COVID-19

    Vaccines, Vol. 9, Núm. 6

2020

  1. Comparing different domains of analysis for the characterisation of N-glycans on monoclonal antibodies

    Journal of Pharmaceutical Analysis, Vol. 10, Núm. 1, pp. 23-34

  2. Comprehensive biophysical and functional study of ziv-aflibercept: characterization and forced degradation

    Scientific Reports, Vol. 10, Núm. 1

  3. Intact charge variant analysis of ziv-aflibercept by cationic exchange liquid chromatography as a proof of concept: Comparison between volatile and non-volatile salts in the mobile phase

    Journal of Pharmaceutical and Biomedical Analysis, Vol. 185

  4. Leachables from plastic materials in contact with drugs. State of the art and review of current analytical approaches

    International Journal of Pharmaceutics, Vol. 583

  5. Randomized, double-blind, controlled trial, phase III, to evaluate the use of platelet-rich plasma versus hyaluronic acid in hip coxarthrosis

    Revista Espanola de Cirugia Ortopedica y Traumatologia, Vol. 64, Núm. 2, pp. 134-142